RA
ARQT icon

Royce & Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Royce & Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-374,540
Closed -$5.25M – 766
2025
Q2 		$5.25M Buy
374,540
+106,928
+40% +$1.5M 0.05% 451
2025
Q1 		$4.19M Buy
+267,612
New +$3.77M 0.05% 471

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royce & Associates's ARQT Position: Q3 2025 in Review

Royce & Associates sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 374,540 shares — an estimated $5.25M sold.

Royce & Associates first reported a position in ARQT in Q1 2025 and held it in 2 quarters. The position peaked at $5.25M in Q2 2025. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • Royce & Associates reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Royce & Associates sold 374,540 Arcutis Biotherapeutics shares in Q3 2025, an estimated $5.25M.
  • Royce & Associates first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 2 quarters.
  • Royce & Associates's Arcutis Biotherapeutics position peaked at $5.25M in Q2 2025.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Royce & Associates's 13F filing for Q3 2025, filed 12 Nov 2025.